Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02814669
Title Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche

prostate adenocarcinoma


Atezolizumab + Radium Ra 223 dichloride

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.